Browsing by Subject "Adiponectin"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Publication
    Open Access
    A Systematic Review and Meta-Analysis of Serum Adiponectin Measurements in the Framework of Dog Obesity
    (2020-09-14) Muñoz-Prieto, Alberto; Cerón, José Joaquín; Martínez-Subiela, Silvia; Mrljak, Vladimir; Tvarijonaviciute, Asta; Medicina y Cirugía Animal
    Adiponectin is an abundant plasma protein that is closely related to obesity and obesity-related pathologies. The molecule can be found in three different isoforms, each with different biological activities. Studies on canine obesity have suggested that adiponectin concentrations are decreased in obesity; however, no canine meta-analyses have been performed that feature all the required data. The aim of this study is to perform a systematic review and meta-analysis of studies that pertain to total and high molecular weight (HMW) adiponectin in relation to canine obesity. From 20 different studies, a total of 366 dogs with obesity and 349 normal weight dogs are included in the meta-analysis. Client-owned dogs were most represented, accounting for 54.3% of the dogs used, while experimental dogs enrolled in the studies made up the remaining 45.7%. The concentrations of total adiponectin in dogs with obesity were significantly lower compared with normal weight dogs. Additionally, adiponectin concentrations were significantly higher in dogs after a successful weight loss protocol compared to the start of the protocol and were significantly lower in dogs after gaining weight. In conclusion, although caution should be taken due to the relatively low number of studies that exist and the high heterogeneity between them, this meta-analysis indicates that adiponectin is decreased in obese dogs.
  • Thumbnail Image
    Publication
    Restricted
    Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system
    (Elsevier, 2011-11-15) Asensio López, María del Carmen; Lax Pérez, Antonio Manuel; Pascual Figal, Domingo A; Valdés, Mariano; Sánchez Mas, Jesús; Medicina
    Doxorubicin has cardiotoxic effects that limit its clinical benefit in cancer patients. Metformin exerts cardioprotective actions via AMP-activated protein kinase (AMPK) and increases the expression of adiponectin and its receptors (adipoR1 and adipoR2) in skeletal muscle and adipose tissue, but its effect on cardiac tissue is still unknown. This work aimed to study whether metformin exerts any protective action against the cardiotoxicity of doxorubicin and whether the cardiac system of adiponectin is involved in any such action. The addition of doxorubicin (5μM) to adult mouse cardiomyocytes (HL-1 cell line) induced apoptosis, which was characterized by a loss of cell viability, activation of caspases, and fragmentation of the genetic material. Doxorubicin treatment also caused a decrease in the activity of the antioxidant enzymes catalase, glutathione peroxidase, and superoxide dismutase. Pretreatment with metformin (4mM, 24h) provided protection against doxorubicin-induced damage. This pretreatment significantly increased cell viability, attenuated the activation of caspases and the fragmentation of genetic material, and restored the antioxidant activity. In addition, metformin up-regulated the expression of adiponectin and its receptors, adipoR1 and adipoR2, in cardiomyocytes. In contrast, silencing either adipoR1 or adipoR2 with siRNA inhibited the AMPK activation and the protective effects of metformin. Taken together, these results demonstrate that metformin protects cardiomyocytes from doxorubicin-induced damage and that the cardiac adiponectin system plays an important role in this protective action.
  • Thumbnail Image
    Publication
    Embargo
    Salivary adiponectin, but not adenosine deaminase, correlates with clinical signs in women with Sjögren’s syndrome: a pilot study
    (https://link.springer.com/, 2018-07-20) Tvarijonaviciute, Asta; Zamora, Carmen; Martinez-Subiela, Silvia; Tecles, Fernando; Pina, Francisca; Lopez Jornet, Pia; Dermatología, Estomatología, Radiología y Medicina Física
    Objectives To evaluate salivary adiponectin and adenosine deaminase (ADA) in women suffering from Sjögren’s syndrome (SS). Methods Salivary adiponectin and ADA were measured in patients with SS (n = 17) and compared to their values in healthy controls (n = 13) and patients suffering from drug-induced xerostomia (non-SS sicca group; n = 19). A clinical history was made for each patient, patients were examined clinically, and xerostomia inventory (XI) was performed. Results Salivary adiponectin corrected by total protein was higher in patients with SS than in healthy individuals (P < 0.05) or patients with non-SS sicca (P < 0.01) and correlated with XI (r = 0.555; P < 0.05). Salivary ADAwas higher in patients with SS and non-SS sicca compared to controls (P<0.05 in both cases). Conclusion The results of the present study indicate that adiponectin and ADA are increased in the saliva of patients with SS. Clinical relevance Salivary adiponectin corrected by total protein can be a potential biomarker of SS.
  • Thumbnail Image
    Publication
    Embargo
    Salivary adiponectin, but not adenosine deaminase, correlates with clinical signs in women with Sjögren's syndrome: a pilot study
    (2019-03) López Jornet, María Pía; Tvarijonaviciute, Asta; Zamora, Carmen; Martinez Subiela, Silvia; Tecles, Fernando; Pina, Francisca; Dermatología, Estomatología, Radiología y Medicina Física
    Abstract Objectives: To evaluate salivary adiponectin and adenosine deaminase (ADA) in women suffering from Sjögren's syndrome (SS). Methods: Salivary adiponectin and ADA were measured in patients with SS (n = 17) and compared to their values in healthy controls (n = 13) and patients suffering from drug-induced xerostomia (non-SS sicca group; n = 19). A clinical history was made for each patient, patients were examined clinically, and xerostomia inventory (XI) was performed. Results: Salivary adiponectin corrected by total protein was higher in patients with SS than in healthy individuals (P < 0.05) or patients with non-SS sicca (P < 0.01) and correlated with XI (r = 0.555; P < 0.05). Salivary ADA was higher in patients with SS and non-SS sicca compared to controls (P < 0.05 in both cases). Conclusion: The results of the present study indicate that adiponectin and ADA are increased in the saliva of patients with SS. Clinical relevance: Salivary adiponectin corrected by total protein can be a potential biomarker of SS. Trial registration: NCT03156569.